Rapidly changing regulation and surging patient-care demand tied to reform is creating significant demand for next generation technology solutions from health care providers. Athenahealth (NASDAQ:ATHN) has been one of the biggest beneficiaries of this trend, but earnings per share have typically fallen short of analyst projections, creating hurdles for share prices.
In the following slideshow, I offer a refresher on Athenahealth's products, challenges, and opportunities that will help you better understand the company when it reports earnings on July 18.
Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.
Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioend. The Motley Fool recommends Athenahealth. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.